Cargando…
Emerging cancer therapies and granulocyte-colony stimulating factor in febrile neutropenia patients presenting to the emergency department during the COVID-19 pandemic era
Autores principales: | Lai, Wei-Jen, Hsu, Chen-Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112942/ https://www.ncbi.nlm.nih.gov/pubmed/37088670 http://dx.doi.org/10.1016/j.ajem.2023.04.021 |
Ejemplares similares
-
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009) -
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010) -
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014) -
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010) -
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)